Zhenshun Fund

Zhenshun Fund

Zhenshun Fund was founded in Beijing by Charles Xue, a prominent angel investor and early backer of several U.S.-listed Chinese tech companies. The firm emerged during China's first wave of organized angel activity, translating Xue's personal network — built across decades of operating and investing in both China and the U.S. — into an institutional early-stage strategy. Xue, a veteran of China's internet sector since the late 1990s, positioned the fund as a bridge for Chinese capital into Silicon Valley and for U.S.-trained entrepreneurs returning to China. The firm deploys primarily at seed and Series A, with some follow-on into growth rounds. Its mandate spans enterprise software, fintech, digital health, AI/ML, and mobility — asset classes where technical founders benefit from cross-border market access. The portfolio has included notable U.S.-based consumer and enterprise names alongside Chinese startups; Xue's personal investment track record includes early checks in companies such as Pactera and Jumei International, and his network connections extend to multiple Y Combinator and 500 Startups cohorts. The firm invests in both direct equity and convertible structures, and has participated in rounds syndicated by other China-U.S. venture platforms. The firm operates without publicly disclosed AUM or headcount, typical of China's unregistered early-stage investment vehicles. Its Beijing headquarters anchors a presence that has historically included activity in the San Francisco Bay Area, reflecting its cross-border thesis. In addition to direct venture investing, Xue has been a frequent speaker and mentor within China's tech ecosystem, advising organizations on startup formation and fundraising. Zhenshun Fund reflects a structural model that gained currency in the 2010s but has become rarer under tightened cross-border capital controls: a single-GP vehicle moving deal flow bi-directionally between Chinese LPs and U.S.-domiciled startups. This architecture gave the firm an early-mover advantage in accessing Silicon Valley rounds before U.S. funds routinely courted Chinese limited partners, but it also exposes the firm to regulatory friction in both jurisdictions — a genuine differentiator from purely domestic venture franchises.